* To identify the incidence of LIT among critically ill patients, as limited studies have only addressed this population. * To evaluate the impact of several factors on the incidence of LIT, the time to onset of LIT, and the time to recovery of platelets. * To study the effect of concurrent medications (enoxaparin, unfractinated heparin, piperacillin, carbapenems, tigecycline, fluconazole or voriconazole, digoxin, amiodarone, acetaminophen, tirofiban, statins, and antiepileptics) frequently used in critically ill patients on the incidence of LIT. * To investigate the impact of possible medications with an antioxidant effect on the prevention of LIT. * To assess the impact of LIT on composite end point (mortality, bleeding, and length of stay)
Study Type
OBSERVATIONAL
Enrollment
310
Linezolid 600mg injection
15 May hospital
Cairo, Egypt
RECRUITINGIncidence of Linezolid-induced thrombocytopenia (LIT) thrombocytopenia
Defined as platelets \< 150000 OR decrease \> 50% of baseline platelets.
Time frame: One year
Time to the onset of LIT
Defined as platelets \< 150000 OR decrease \> or = 50% of baseline platelets.
Time frame: One year
time to platelet recovery
after having thrombocytopenia, regardless of discontinuation of linezolid, recovery is defined as the restoration and maintenance of platelet counts \> 70% of baseline values
Time frame: One year
Incidence of clinical outcomes
Incidence of clinical outcomes (bleeding, mortality, length of stay, need for platelet or blood transfusion).
Time frame: One year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.